extensive previous research on complex systems science and evolutionary bi ology, as summarized by authors, including , LaFollette and Shanks (1996) , LaFollette and Shanks (1998) , Shanks and Greek (2008) , and . TSMT states: "While trans-species extrapolation is possible when perturbations concern lower levels of organization or when studying morphology and function on the gross level, one evolved complex sys tem will not be of predictive value for another when the perturbation affects higher levels of organization" ( Greek and Hansen, 2013, p. 254 ) . That is, according to science, the observation of a drug response in one species is uninformative about the drug response in another species. This theory is based on complex ity science, evolutionary biology, and empirical evidence. In the remainder of this article, we explain why the fields of complexity science and evolutionary biology are relevant to understanding animal modeling and evaluating the in ability of animal models to predict human response to drugs and disease. LaFollette and Shanks (1996) and the Medical Research Modernization Committee (2006) were among the first to document systematically the meth odological failure of using one evolved complex system to model another, in terms of predicting outcomes. Subsequent work by Greek and Hansen (2013) , , Shanks and Pyles (2007) , and Medicine, 2016) (Gell-Mann, 1994; Gleick, 2008; Goodwin, 2001 Rosen (1999, p. 392) (Belmaker et al., 2012; Bell and Spector, 2011; Bruder et al., 2008; Castillo-Fernandez et al., 2014; Chapman and Hill, 2012; Czyz et al., 2012; Dempster et al., 2011; LeCouter et al., 1998; Raineri et al., 2001; Pearson, 2002 ) . (Gleick, 2008 Ahn et al. (2006) , Gell-Mann (1994) , Goodwin (2001) , Greek (2013c) , , Kitano (2002) ; Morowitz (2002) , Sole and Goodwin (2002) , Van Regenmortel (2004a, b) , Van Regenmortel and Hull (2002), Vojinovic (2015a, b Northrop (2011, p. xiii) ( Graham, 2002 ) . (Kasowski et al., 2010; Marchetto et al., 2013; Morley et al., 2004; Pritchard et al., 2006; Rifkin, Kim and White, 2003; Rosenberg et al., 2002; Sandberg et al., 2000; Seok et al., 2013; Storey et al., 2007; Suzuki and Nakayama, 2003; Warren et al., 2014; Zhang et al., 2008 
then led to the development of TSMT, which is the only theory (we intention ally use the word theory as opposed to hypothesis; see National Academies of Science Engineering

The reasons humans do not normally grow a tail during devel opment is that the gene is never turned on ( or expressed). Differences in gene regulation and expression vary within and between species and account for differences in response to drugs and disease
In reality, patients are assessed with a chest x-ray instead of a CT scan because an x-ray is quicker, easier, and less expensive than a CT scan, and clinically significant collapses are detected by x-ray a very, very high percentage of the time. To determine the predictive value of the chest x-ray, one would perform both diagnostic tests on a group of patients and the calculations in
Test:
Calculations: Graham et al. (2005) and Attarwala (2010) Greek and Greek (2004) , Greek, Menache and Rice (2012) , and , and is summarized by Kramer and Greek (2018 Data from Suter (1990) and the nth edition of the Catalog of Te ratogenic Agents (Shepard and Lemire, 2004) Greek (2013a Greek ( , b, 2014b , Greek and Greek (2010 ) , and Seok et al. (2013) Dolgin (2013, p. 118) , puts Seok's and col leagues' findings in context: "Yet, The failure of animal models in these cases appears to be due to differences in gene response between humans and mice (Seok et al., 2013; Warren et al., 2014) (Enna and Williams, 2009; Hau, 2003; Lin, 1995 Devoy et al., 2012; Groenink, Folkerts and Schuurman, 2015; Katzner et al., 2009; National Science Foundation, 2011; Rudczynski, 2011; van Meer, Graham and Schuurman, 2015 (Bailey, 2008; Editorial, 2007; Gamble and Mat thews, 2010 ) . More than a thousand drugs have been seen to protect against nervous system damage in animal models of stroke. Again, none have been protective in humans (Dimagl, 2006; Dimagl and Macleod, 2009; Macleod, 2004; O'Collins et al., 2011; O'Collins et al., 2006; Sena et al., 2007 ) . Fouad, Hurd and Magnuson (2013) smith (2011a, b ) , Chiou et al. (2000 ) , Ennever et al. (1987) , Fletcher (1978) , Grass and Sinko (2002) , Hughes (2008) , Litchfield (1962) , Igarashi et al. (1995 Igarashi et al. ( , 1996 , Johnson et al. (2001) , Kola and Landis (2004) , Kummar et al. (2007) , Lesko and Woodcock (2004) , Lumley (1990) , Mahmood (2000) , Smith and Caldwell (1977) , Spriet-Pourra and Auriche (1994) , van Meer et al. (2012) , and Weaver et al. (2003) Biomedictracker and Amplion, 2016; Smietana, Siatkowski and Moller, 2016 Kramer and Greek (2018) explain the obstacles that must be overcome to ensure that drug development and the study of diseases are based on sound science. This will require changes to the regulations that currently mandate the use of animal models. Furthermore, Kramer and Greek (2018) 
inadequate. Drugs that harm even a very small percentage of patients, even one out of 1,000, have been pulled off the market because of life-threating side effects, such as total liver failure, heart attack, or stroke. Examples of widely marketed drugs that have been withdrawn due to unanticipated fatalities in clude Vioxx ( rofecoxib ), Propulsid ( cisapride ), and Rezulin ( troglitazone ). See
